SCHEMBL16832378

SCHEMBL16832378

COc1ccc2c(C(=O)O)cc(C(N)=O)nc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM2 Q14416 6/20 0.58
▸ KDM4E B2RXH2 7/20 0.58
▸ ALDH1A1 P00352 2/20 0.58
▸ HPGD P15428 2/20 0.58
▸ POLB P06746 2/20 0.58
▸ HSD17B10 Q99714 1/20 0.58
▸ LMNA P02545 2/20 0.50
▸ NPC1 O15118 2/20 0.50
▸ RAB9A P51151 2/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ MAPT P10636 1/20 0.50
▸ NFKB1 P19838 1/20 0.50
▸ NFKB2 Q00653 1/20 0.50
▸ RELA Q04206 1/20 0.50
▸ ATM Q13315 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ CYP2D6 P10635 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16832417 0.90 KDM4E (0.72) GRM2KDM4EALDH1A1HPGDPOLB
SCHEMBL16832123 0.90 KDM4E (0.58) GRM2KDM4EALDH1A1HPGDPOLB
SCHEMBL16832831 0.88 NQO2 (0.60) GRM2KDM4EHPGDSTACR3
SCHEMBL26965977 0.84 KDM4E (0.81) KDM4EALDH1A1HPGDPOLBHSD17B10
SCHEMBL15129579 0.80 KDM4E (0.73) KDM4EALDH1A1HPGDPOLBHSD17B10
SCHEMBL18484084 0.80 GRM2 (0.54) GRM2KDM4EALDH1A1MAPTNPSR1
SCHEMBL16832328 0.80 PLA2G2A (0.64) GRM2KDM4EALDH1A1HPGDPOLB
SCHEMBL16832238 0.78 GRM2 (0.51) GRM2ALDH1A1HPGDPOLBHSD17B10
SCHEMBL16832747 0.78 GRM2 (0.51) GRM2ALDH1A1
SCHEMBL16832253 0.77 KDM4E (0.58) GRM2KDM4EPOLBLMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170037028-A1 GLUCOSE TRANSPORT INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-02-09 — — US disclosed
US-20170037028-A1 GLUCOSE TRANSPORT INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-02-09 — — US disclosed
US-20170037028-A1 GLUCOSE TRANSPORT INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-02-09 — — US disclosed
EP-3083598-A1 GLUCOSE TRANSPORT INHIBITORS Bayer Pharma Aktiengesellschaft (DE) 2016-10-26 — — EP disclosed
CN-106029647-A Glucose transport inhibitors 拜耳制药股份公司 2016-10-12 — — CN disclosed
WO-2015091428-A1 GLUCOSE TRANSPORT INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-06-25 — — WO disclosed
WO-2015091428-A1 GLUCOSE TRANSPORT INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-06-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170037028-A1 GLUCOSE TRANSPORT INHIBITORS SLC2A1, SLC2A2, SLC2A4 GRM2 817/4885KDM4E 3458/4885ALDH1A1 432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback